SPAI experienced a dramatic 72% revenue collapse while simultaneously raising substantial capital, resulting in a 37% increase in outstanding shares and massive operating losses.
The company appears to be in a critical transition phase, burning through cash at an accelerated rate with operating losses doubling to $14.5M despite having strengthened its balance sheet through equity financing. The severe revenue decline coupled with increased R&D spending suggests either a major pivot in business strategy or significant operational challenges in their core markets.
SPAI's financials show a company in financial distress despite recent capital infusion - revenue plummeted 72% to just $607K while operating losses doubled to $14.5M, indicating severe operational challenges. However, the company significantly strengthened its balance sheet through equity financing, with current assets surging 552% to $17.9M and stockholders' equity growing 357% to $17.7M, though this came at the cost of 37% dilution in outstanding shares. The massive increase in R&D spending (336%) combined with collapsing gross profit margins suggests the company is heavily investing in new technology while struggling with its existing revenue streams.
Current assets grew 551.9% — improving short-term liquidity or inventory/receivables build.
Equity base grew 357.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
R&D investment increased 336.2% — signals commitment to future product development, though near-term margin impact.
Asset base grew 286.2% — expansion through organic growth, acquisitions, or capital deployment.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 92.8% — review whether driven by operations, interest costs, or non-recurring items.
Inventory surged 79.8% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Revenue declined 72% — significant demand weakness or market share loss warrants investigation.
SG&A up 69.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →